Sarfez Pharmaceuticals, Inc.
11
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
27.3%
3 terminated/withdrawn out of 11 trials
70.0%
-16.5% vs industry average
55%
6 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs
Role: lead
Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal
Role: lead
Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
Role: lead
Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
Role: lead
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
Role: lead
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
Role: lead
Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
Role: lead
A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
Role: lead
Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects
Role: lead
A Food Effect Study of 60mg ER Torsemide
Role: lead
Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects
Role: lead
All 11 trials loaded